ZYBERNO
Stock Report
Updated Aug 31, 2026

Cue Biopharma, Inc. (CUE)

Healthcare • NASDAQ

$27.90

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
22.0/100
POOR BUSINESS
Cue Biopharma, Inc. (CUE) scores 22/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-1,162.6%)
Debt-to-Equity (Solvency Risk):CRITICAL (2.66x)
Operating Margin (Operational Efficiency):CRITICAL (-317.6%)
Return on Capital (Capital Efficiency):CRITICAL (-673.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Cue Biopharma, Inc. (CUE) stock report — Zyberno Score 22/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, CUE generated -$24.61M in Owner Earnings. Capital was deployed as follows: $148.00K invested in capital expenditures. Reinvestment rate: 0.9%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:27.90
Market Cap:$176.91M

Valuation Multiples (3)

P/B Ratio:76.58x
P/S Ratio:4.70x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$162.59M

Price Action & Momentum (1)

% of 52-Week High:61.3%
B. Profitability Assessment

Return Metrics (5)

ROA:-545.9%
Reinvestment Rate:0.9%
Fundamental Growth Rate (g):-5.9%

Margin Analysis (3)

Operating Margin Ttm:-317.6%
Net Margin Ttm:-490.9%
Ebitda Margin:-314.0%

TTM Performance (2)

Operating Margin Ttm:-317.6%
Net Margin Ttm:-490.9%

Yield Metrics (2)

Earnings Yield:-$82.05
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-28,510.4%
Latest Earnings Filed:2026-08-14

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):100.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.25x
Quick Ratio:1.25x
Cash Ratio:0.82x

Leverage Analysis (3)

Debt To Equity Ttm:2.66x
Debt-to-Equity Ratio:2.66x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:5,405,000.00
Cash And Cash Equivalents:17,392,000.00
Long Term Debt:$1.45M
Net Debt:-$14.32M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $37.65M
Linear Growth: 100.0%
📊 Click to view full CUE Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$119.60M

Bottom Line Performance (3)

-$184.85M
Income Before Tax:$0.00
Ebitda Ttm:-118,243,000.00

Operating Expenses (5)

Operating Expenses:136,320,000.00
R And D Expense:77,190,000.00
Sga Expense:59,109,000.00
Income Tax Expense:$413.00K
Interest Expense:-193,000.00

Expense Ratios (3)

R And D To Revenue Percentage:979.9%
Sga To Revenue Percentage:750.4%
Ebitda Margin:-314.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$30.71M
Current Assets:$26.62M
Ppe Net:4,025,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:28,397,000.00
Current Liabilities:21,218,000.00
Long Term Debt:$1.45M
Short Term Debt:$1.63M

Equity & Capital (3)

Equity:$2.31M
Retained Earnings:-$526.71M
Common Stock:300,000,000.00

Working Capital Items (3)

Accounts Receivable:5,377,000.00
Inventory:0.00
Accounts Payable:14,883,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:23,838,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$24.46M-$24.61M

Investment Activities (2)

Investing Cash Flow:-$121.00K
Capital Expenditures Ttm:148,000.00

Financing Activities (3)

Financing Cash Flow:$306.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:28,289,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$100.00K

Non-Cash Items (1)

Depreciation Amortization Ttm:1,357,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-25.50
-$25.50
Earnings Per Share Ttm:-$29.15

Revenue & Cash Per Share (2)

Sales Per Share Ttm:5.94
Operating Cash Flow Per Share:-$3.42

Book Value & Capital (2)

Book Value Per Share:$0.36
Cash Per Share:2.74

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:1.11x
Working Capital Turnover Ttm:6.97x

Receivables Management (2)

Receivables Turnover Ttm:7.00x
Days Sales Outstanding Ttm:52.12

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:144.27
Cash Conversion Cycle:-1,091.15
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$24.61M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.9%
Fundamental Growth Rate (g):-5.9%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):100.0%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-40.1%
C. Company Profile & Context

Corporate Information (6)

Symbol:CUE
Company Name:Cue Biopharma, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:6.34M
Shares Outstanding Basic:6.34M
Shares Outstanding Diluted:6.34M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 14:38:09 UTC
Data Timestamp:2026-08-19T10:18:28.949936
Scroll to Top